Ascendis Pharma/$ASND
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
- Ticker
- $ASND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,189
- Headquarters
- Hellerup, Denmark
- Website
- ascendispharma.com
Ascendis Pharma Metrics
BasicAdvanced
$15B
17.35
$13.14
-
-
Price and volume
Market cap
$15B
52-week high
$282.15
52-week low
$203.80
Average daily volume
781K
Financial strength
Current ratio
2.991
Quick ratio
2.229
Long term debt to equity
0.268
Total debt to equity
0.313
Interest coverage (TTM)
2.01%
Profitability
EBITDA (TTM)
295.545
Gross margin (TTM)
91.30%
Net profit margin (TTM)
70.84%
Operating margin (TTM)
24.70%
Effective tax rate (TTM)
-658.14%
Revenue per employee (TTM)
$987,190
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
118.78%
Valuation
Price to earnings (TTM)
17.35
Price to revenue (TTM)
12.036
Price to book
10.43
Price to tangible book (TTM)
10.45
Price to free cash flow (TTM)
37.603
Free cash flow yield (TTM)
2.66%
Free cash flow per share (TTM)
6.064
Growth
Revenue change (TTM)
113.35%
Earnings per share change (TTM)
-356.73%
3-year revenue growth (CAGR)
106.35%
10-year revenue growth (CAGR)
66.26%
3-year earnings per share growth (CAGR)
2.54%
10-year earnings per share growth (CAGR)
18.61%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Analyst projections of the future price of Ascendis Pharma stock.
Bulls say / Bears say
YORVIPATH is showing strong commercial traction: Q2 product revenue reached €315 million, including €252 million from YORVIPATH, which was available commercially or through named-patient programmes in more than 35 countries. Five-year and 3.5-year data also support durable efficacy, safety and independence from conventional therapy. (Ascendis Pharma, GlobeNewswire)
YUVIWEL could add a second meaningful growth pillar. Its first US quarter generated €8 million, more than 220 patients had enrolled by the end of July, and longer-term achondroplasia data showed sustained improvements in growth and body proportionality, while infant-trial enrolment was completed. (Ascendis Pharma, GlobeNewswire)
Ascendis has moved towards self-funded growth. It ended Q2 with €812 million in cash and no bank or convertible debt, reported a €92 million non-IFRS operating profit, and expects more than €500 million of operating cash flow in 2026. (The Motley Fool, Ascendis Pharma)
The business remains highly reliant on YORVIPATH: it produced €252 million of Q2 product revenue, versus €55 million for SKYTROFA and €8 million for YUVIWEL. At the same time, selling, general and administrative costs rose to €173 million from €108 million, so a slowdown in the lead product could quickly weaken operating leverage. (Ascendis Pharma)
The BioMarin settlement removes litigation uncertainty but comes with an economic cost: reported terms include royalties of 18% to 20% on YUVIWEL net sales until May 2030. Those payments could materially reduce the product's long-term margin and cash contribution. (Yahoo Finance, Simply Wall St)
Further achondroplasia growth still depends on regulatory and clinical execution. YUVIWEL's European application remained under review, while the first infant evidence came from a seven-infant sentinel cohort ahead of the larger double-blind trial, leaving meaningful approval and efficacy risk. (Ascendis Pharma, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ascendis Pharma News
AllArticlesVideos
Funds containing Ascendis Pharma
AllUSDGBP
Fund name | Fund size | $ASND weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.94% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.94% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.